Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Astrazeneca Plc ADR (NQ: AZN )

72.71 -0.37 (-0.51%)
Streaming Delayed Price Updated: 10:56 AM EDT, Jun 1, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1,018,608
Open 72.28
Bid (Size) 72.71 (7)
Ask (Size) 72.72 (2)
Prev. Close 73.08
Today's Range 71.89 - 72.76
52wk Range 52.65 - 76.56
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
LYNPARZA® (olaparib) plus abiraterone approved in the US for the treatment of BRCA-mutated metastatic castration-resistant prostate cancer
From AstraZeneca
Via Business Wire
Rotation Out Of Healthcare And Biotech Stocks: Age Of Disruption?
A steady rotation out of biotech and healthcare stocks into the Nasdaq-100 large-cap tech stocks can be unnerving for portfolio managers. 
Via Talk Markets

Performance

YTD
+4.88%
+4.88%
1 Month
-1.07%
-1.07%
3 Month
+11.50%
+11.50%
6 Month
+6.97%
+6.97%
1 Year
+9.37%
+9.37%

More News

Read More
Nvidia Becomes Ninth Company To Hit $1 Trillion Market Cap — Who Could Be Next To Join Elusive Club?
Via Benzinga
$1000 Invested In This Stock 5 Years Ago Would Be Worth $2,000 Today
Via Benzinga
Is AstraZeneca Stock a Buy for Growth Investors?
Via The Motley Fool
AstraZeneca Unusual Options Activity
Via Benzinga
Want to Grow Richer? These Stocks Have Doubled in the Past 5 Years
Via The Motley Fool
Amazon's Prime Video Trolls Netflix's Password Crackdown, Tesla Data Leak Exposes Safety Nightmare, Elon Musk's Brain Chip Company Gets FDA Nod For Human Trial: Top Stories For Today
Via Benzinga
IMFINZI® (durvalumab) plus LYNPARZA® (olaparib) and IMFINZI alone both significantly improved progression-free survival in advanced endometrial cancer when added to chemotherapy
From AstraZeneca
Via Business Wire
AstraZeneca/Merck's Cancer Drug Combo Shows Positive Results In Endometrial Cancer
Via Benzinga
AstraZeneca will highlight momentum of practice-changing cancer medicines across its robust pipeline at ASCO 2023
From AstraZeneca
Via Business Wire
As Debt Ceiling Talks Wobble, Investors Look To May Fed Minutes, Nvidia Earnings For Direction
Via Benzinga
AstraZeneca-Spin Off Entasis Secures FDA Approval For First Pathogen-Targeted Therapy Addressing Acinetobacter
Via Benzinga
New AstraZeneca Data Presented at ATS 2023 Strengthen the Body of Evidence Supporting Early Intervention With BREZTRI in COPD
From AstraZeneca
Via Business Wire
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
Week In Review: LaNova Sells Pre-Clinical ADC To AstraZeneca In $600 Million Deal
Via Talk Markets
3 Undervalued Pharma Stocks to Buy for High Total Returns
Via InvestorPlace
WHO Recommends New COVID Booster Shots To Target XBB Variants, Despite Slower Uptake
Via Benzinga
DeSantis Vs. Disney, Alibaba Spinoffs Cloud Business, Apple Bans Internal ChatGPT Use: Today's Top Stories
Via Benzinga
AstraZeneca's China Executive Seeks Loyalty to "Love the Communist Party" In China
Via Benzinga
The 7 Next Trillion-Dollar Companies to Invest in Now
Via InvestorPlace
Apple Thwarts $2B In Fraud Transactions, UBS Takes $17B Hit From 'Hasty Credit Suisse Takeover,' Verizon Streamlines Unlimited Data Plans: Today's Top Stories
Via Benzinga
One More Quits US Pharma Lobby Group: AstraZeneca Follows Teva, AbbVie Footsteps
Via Benzinga
AstraZeneca' Tagrisso/Chemo Combo Therapy Delays Treatment Resistance, Disease Progression In Certain Type Of Advanced Lung Cancer
Via Benzinga
TAGRISSO® (osimertinib) plus chemotherapy demonstrated strong improvement in progression-free survival for patients with EGFR-mutated advanced lung cancer in FLAURA2 Phase III trial
From AstraZeneca
Via Business Wire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.